Company intelligence / Profile preview

Iteria Biopharma

Touro/A Coruña*, Galicia, Spainiteriabiopharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Iteria Biopharma is a Spanish biotech founded in late 2024 focused on discovering precision drugs for oncology. Its lead program addresses castration-resistant prostate cancer, building upon GalChimia’s MAOPROST project. The company is privately funded by its founders and aims to expand both capital and staff through additional fundraising in 2025. No clinical results are available yet as programs are at the preclinical stage.

Therapeutic areas: Oncology
Modalities: Small molecules / New Chemical Entities (NCEs) targeting challenging cancer targets
Industry: Biotech

Drug pipeline

3 assets

ITR-XXX

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

GalChimia – chemistry services partner and co-founder/contributor to lead program development

Beyond the preview

Go deeper on Iteria Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iteria Biopharma.

Explore the full profile